1. Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
- Author
-
Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, Scharpf M, Loewe L, Todenhoefer T, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, and Kruck S
- Subjects
- Aged, Humans, Male, Middle Aged, Perineum diagnostic imaging, Prostate diagnostic imaging, Prostatic Neoplasms pathology, Rectum diagnostic imaging, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Early Detection of Cancer instrumentation, Image-Guided Biopsy, Magnetic Resonance Imaging, Interventional, Prostate pathology, Prostatic Neoplasms diagnostic imaging, Ultrasonography, Interventional
- Abstract
Objective: To evaluate the performance of transperineal robot-assisted (RA) targeted (TB) and systematic (SB) prostate biopsy in primary and repeat biopsy settings., Patients and Methods: Patients underwent RA biopsy between 2014 and 2016. Before RA-TB, multiparametric magnetic resonance imaging (mpMRI) was performed. Prostate lesions were scored (Prostate Imaging, Reporting and Data System, version 2) and used for RA-TB planning. In addition, RA-SB was performed. Available, whole-gland pathology was analysed., Results: In all, 130 patients were biopsy naive and 72 had had a previous negative transrectal ultrasonography-guided biopsy. In total, 202 patients had suspicious mpMRI lesions. Clinically significant prostate cancer was found in 85% of all prostate cancer cases (n = 123). Total and clinically significant prostate cancer detection rates for RA-TB vs RA-SB were not significantly different at 77% vs 84% and 80% vs 82%, respectively. RA-TB demonstrated a better sampling performance compared to RA-SB (26.4% vs 13.9%; P < 0.001)., Conclusion: Transperineal RA-TB and -SB showed similar clinically significant prostate cancer detection rates in primary and repeat biopsy settings. However, RA-TB offered a 50% reduction in biopsy cores. Omitting RA-SB is associated with a significant risk of missing clinically significant prostate cancer., (© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF